Roche lung cancer blockbuster wins approval in early-stage NSCLC

2024-04-19

上市批准临床3期临床结果抗体药物偶联物

Roche's Genentech announced that its blockbuster lung cancer treatment, Alecensa, has been approved for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), making it the first ALK inhibitor ALK inhibitor approved in this indication.

The approval is based on positive results from the phase 3 ALINA study that demonstrated Alecensa reduced the risk of disease recurrence or death by 76% compared with platinum-based chemotherapy in people with completely resected IB to IIIA ALK-positive NSCLC.

According to Roche, about half of people living with early-stage NSCLC experience disease recurrence following surgery despite adjuvant chemotherapy; Alecensa can now address this unmet need.

Alecensa was first approved in late 2015 to treat people with advanced ALK-positive NSCLC whose disease had worsened after, or who could not tolerate treatment with tyrosine kinase inhibitor, Xalkori. Its approval was expanded in 2017, enabling the drug to be used as a first-line treatment for people with advanced ALK-positive NSCLC.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构